Here is the financial summary for Balaji Amines Limited: **1. Financial Highlights:** Consolidated Q1FY26 revenue was ₹367 Cr, up QoQ but down YoY.

EBITDA & PAT declined sequentially and annually despite volume growth to 27,570 MT.

Standalone results remained stable with ₹327 Cr revenue and ₹64 Cr EBITDA. **2. Strategic Initiatives & Growth Drivers:** Significant capex is underway, including a ₹750 Cr expansion at Balaji Speciality Chemicals for new products (HCN, EDTA) by FY2026-27. Multiple new projects (Dimethyl Ether, N-Methyl Morpholine, Acetonitrile) are planned for FY2025-26/FY2026-27. A 6 MW AC solar plant was commissioned for cost savings. **3. Business Developments:** The Methylamines plant commissioned Nov 2024. Electronic Grade DMC plant (critical for EV batteries, sole Indian manufacturer) became operational May 2025. The hotel division contributed minimally to revenue. **4. Market Position & Competitive Advantage:** As India's largest Methylamines & aliphatic amines manufacturer, the company leverages indigenous technology and a diverse 40+ product portfolio.

A standalone zero-debt balance sheet and strong exposure to pharma (51%) & agrochemicals (26%) bolster its competitive edge. **5. Investor Implications:** While Q1FY26 consolidated profit dipped, a robust pipeline of high-value specialty chemical projects and capacity expansions signals strong long-term growth potential.

Capital work-in-progress should boost future revenues and margins from FY2025-26 onwards.